Delivery of human factor IX in mice by encapsulated recombinant myoblasts: A novel approach towards allogeneic gene therapy of hemophilia B

Gonzalo Hortelano, Ayman Al-Hendy, Frederick A. Ofosu, Patricia L. Chang

Research output: Contribution to journalArticle

130 Citations (Scopus)

Abstract

A potentially cost-effective strategy for gene therapy of hemophilia B is to create universal factor IX-secreting cell lines suitable for implantation into different patients. To avoid graft rejection, the implanted cells are enclosed in alginate-polylysine-alginate microcapsules that are permeable to factor IX diffusion, but impermeable to the hosts' immune mediators. This nonautologous approach was assessed by implanting encapsulated mouse myoblasts secreting human factor IX into allogeneic mice. Human factor IX was detected in the mouse plasma for up to 14 days maximally at ≃4 ng/mL. Antibodies to human factor IX were detected after 3 weeks at escalating levels, which were sustained throughout the entire experiment (213 days). The antibodies accelerated the clearance of human factor IX from the circulation of the implanted mice and inhibited the detection of human factor IX in the mice plasma in vitro. The encapsulated myoblasts retrieved periodically from the implanted mice up to 213 days postimplantation were viable and continued to secrete human factor IX ex vivo at undiminished rates, hence suggesting continued factor IX gene expression in vivo. Thus, this allogeneic gene therapy strategy represents a potentially feasible alternative to autologous approaches for the treatment of hemophilia B.

Original languageEnglish (US)
Pages (from-to)5095-5103
Number of pages9
JournalBlood
Volume87
Issue number12
StatePublished - Jun 15 1996

Fingerprint

Hemophilia B
Gene therapy
Factor IX
Myoblasts
Human engineering
Genetic Therapy
Plasmas
Antibodies
Graft Rejection
Gene expression
Grafts
Capsules
Cells
Gene Expression
Costs and Cost Analysis
Cell Line

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Delivery of human factor IX in mice by encapsulated recombinant myoblasts : A novel approach towards allogeneic gene therapy of hemophilia B. / Hortelano, Gonzalo; Al-Hendy, Ayman; Ofosu, Frederick A.; Chang, Patricia L.

In: Blood, Vol. 87, No. 12, 15.06.1996, p. 5095-5103.

Research output: Contribution to journalArticle

Hortelano, Gonzalo ; Al-Hendy, Ayman ; Ofosu, Frederick A. ; Chang, Patricia L. / Delivery of human factor IX in mice by encapsulated recombinant myoblasts : A novel approach towards allogeneic gene therapy of hemophilia B. In: Blood. 1996 ; Vol. 87, No. 12. pp. 5095-5103.
@article{6fe89c6817a446ee8220446bab7dc0a9,
title = "Delivery of human factor IX in mice by encapsulated recombinant myoblasts: A novel approach towards allogeneic gene therapy of hemophilia B",
abstract = "A potentially cost-effective strategy for gene therapy of hemophilia B is to create universal factor IX-secreting cell lines suitable for implantation into different patients. To avoid graft rejection, the implanted cells are enclosed in alginate-polylysine-alginate microcapsules that are permeable to factor IX diffusion, but impermeable to the hosts' immune mediators. This nonautologous approach was assessed by implanting encapsulated mouse myoblasts secreting human factor IX into allogeneic mice. Human factor IX was detected in the mouse plasma for up to 14 days maximally at ≃4 ng/mL. Antibodies to human factor IX were detected after 3 weeks at escalating levels, which were sustained throughout the entire experiment (213 days). The antibodies accelerated the clearance of human factor IX from the circulation of the implanted mice and inhibited the detection of human factor IX in the mice plasma in vitro. The encapsulated myoblasts retrieved periodically from the implanted mice up to 213 days postimplantation were viable and continued to secrete human factor IX ex vivo at undiminished rates, hence suggesting continued factor IX gene expression in vivo. Thus, this allogeneic gene therapy strategy represents a potentially feasible alternative to autologous approaches for the treatment of hemophilia B.",
author = "Gonzalo Hortelano and Ayman Al-Hendy and Ofosu, {Frederick A.} and Chang, {Patricia L.}",
year = "1996",
month = "6",
day = "15",
language = "English (US)",
volume = "87",
pages = "5095--5103",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "12",

}

TY - JOUR

T1 - Delivery of human factor IX in mice by encapsulated recombinant myoblasts

T2 - A novel approach towards allogeneic gene therapy of hemophilia B

AU - Hortelano, Gonzalo

AU - Al-Hendy, Ayman

AU - Ofosu, Frederick A.

AU - Chang, Patricia L.

PY - 1996/6/15

Y1 - 1996/6/15

N2 - A potentially cost-effective strategy for gene therapy of hemophilia B is to create universal factor IX-secreting cell lines suitable for implantation into different patients. To avoid graft rejection, the implanted cells are enclosed in alginate-polylysine-alginate microcapsules that are permeable to factor IX diffusion, but impermeable to the hosts' immune mediators. This nonautologous approach was assessed by implanting encapsulated mouse myoblasts secreting human factor IX into allogeneic mice. Human factor IX was detected in the mouse plasma for up to 14 days maximally at ≃4 ng/mL. Antibodies to human factor IX were detected after 3 weeks at escalating levels, which were sustained throughout the entire experiment (213 days). The antibodies accelerated the clearance of human factor IX from the circulation of the implanted mice and inhibited the detection of human factor IX in the mice plasma in vitro. The encapsulated myoblasts retrieved periodically from the implanted mice up to 213 days postimplantation were viable and continued to secrete human factor IX ex vivo at undiminished rates, hence suggesting continued factor IX gene expression in vivo. Thus, this allogeneic gene therapy strategy represents a potentially feasible alternative to autologous approaches for the treatment of hemophilia B.

AB - A potentially cost-effective strategy for gene therapy of hemophilia B is to create universal factor IX-secreting cell lines suitable for implantation into different patients. To avoid graft rejection, the implanted cells are enclosed in alginate-polylysine-alginate microcapsules that are permeable to factor IX diffusion, but impermeable to the hosts' immune mediators. This nonautologous approach was assessed by implanting encapsulated mouse myoblasts secreting human factor IX into allogeneic mice. Human factor IX was detected in the mouse plasma for up to 14 days maximally at ≃4 ng/mL. Antibodies to human factor IX were detected after 3 weeks at escalating levels, which were sustained throughout the entire experiment (213 days). The antibodies accelerated the clearance of human factor IX from the circulation of the implanted mice and inhibited the detection of human factor IX in the mice plasma in vitro. The encapsulated myoblasts retrieved periodically from the implanted mice up to 213 days postimplantation were viable and continued to secrete human factor IX ex vivo at undiminished rates, hence suggesting continued factor IX gene expression in vivo. Thus, this allogeneic gene therapy strategy represents a potentially feasible alternative to autologous approaches for the treatment of hemophilia B.

UR - http://www.scopus.com/inward/record.url?scp=0029890737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029890737&partnerID=8YFLogxK

M3 - Article

C2 - 8652822

AN - SCOPUS:0029890737

VL - 87

SP - 5095

EP - 5103

JO - Blood

JF - Blood

SN - 0006-4971

IS - 12

ER -